Castle Biosciences (CSTL) Q4 2024: 51% Revenue Growth Amid Medicare Coverage Headwinds on Key Test
Castle Biosciences delivered robust 51% revenue growth in 2024 driven by strong test volume expansion across dermatology and gastroenterology, despite looming Medicare non-coverage of its DecisionDx-SCC test. The company faces strategic recalibration as it reallocates commercial focus to its melanoma franchise while navigating reimbursement challenges in 2025. Investors should monitor how Medicare coverage shifts and commercial execution impact growth and margins in the coming quarters.
Summary
- Strategic Reallocation: Medicare non-coverage of DecisionDx-SCC prompts near-total salesforce focus shift to DecisionDx-Melanoma.
- Operational Momentum: TissueCypher’s 130% test report growth reflects expanding gastroenterology footprint and clinical acceptance.
- Capital Discipline: Strong cash position and positive cash flow support measured pipeline investments and potential strategic acquisitions.
Business Overview
Castle Biosciences is a diagnostics company specializing in molecular and genomic tests that guide patient care in dermatology, gastroenterology, and ophthalmology. Its revenue primarily derives from test report volume across key franchises including DecisionDx-Melanoma and DecisionDx-SCC for skin cancers, TissueCypher for Barrett’s Esophagus, and IDgenetix for mental health diagnostics. The company also invests in pipeline development targeting systemic therapy selection in atopic dermatitis.
Performance Analysis
Castle Biosciences reported full-year 2024 revenue of $332.1 million, a 51% increase over 2023, fueled by a 36% rise in total test report volume to 96,071. This growth was broad-based, with dermatologic tests (DecisionDx-Melanoma and DecisionDx-SCC combined) rising 17%, led by an 8% increase in DecisionDx-Melanoma test reports and a 43% surge in DecisionDx-SCC. TissueCypher test reports more than doubled, posting 130% growth, signaling strong adoption in gastroenterology. However, IDgenetix test volumes declined due to strategic commercial realignment.
Gross margins improved to 78.5% for the year, with adjusted gross margin reaching 82%, reflecting operational leverage despite increased personnel and supply costs. The company turned profitable with net income of $18.2 million in 2024, reversing a net loss of $57.5 million in 2023, and generated $64.9 million in operating cash flow, underscoring improved financial health. Notably, the company’s cash and marketable securities rose by $50 million to $293.1 million, providing a strong liquidity buffer.
- Volume Growth Drivers: Dermatology and gastroenterology franchises led volume expansion, with DecisionDx-SCC and TissueCypher showing outsized gains.
- Margin Dynamics: Adjusted gross margin improved despite inflationary pressures, supported by scale and operational efficiency.
- Profitability Turnaround: Positive net income and adjusted EBITDA of $75 million mark a significant inflection from prior losses.
Overall, Castle’s 2024 performance reflects successful commercial execution and product adoption, though upcoming Medicare coverage changes pose a material near-term headwind.
Executive Commentary
"2024 was another exceptional year for Castle, and I'm extremely proud of the strong execution by our entire team... We exited 2024 with roughly 28% market penetration for DecisionDx-Melanoma and 8% for DecisionDx-SCC, demonstrating significant room for growth."
Derek Maetzold, Founder, President and CEO
"We anticipate total revenue of $280 to $295 million in 2025, reflecting the expected loss of Medicare reimbursement for DecisionDx-SCC starting April 24, 2025... We continue to expect to deliver positive net cash flow from operations for the full year 2025."
Frank Stokes, Chief Financial Officer
Strategic Positioning
1. Navigating Medicare Non-Coverage for DecisionDx-SCC
The recent Local Coverage Determination (LCD) finalized by Novitas, effective April 24, 2025, signals non-coverage of DecisionDx-SCC by Medicare. This directly impacts roughly 8% market penetration in a 200,000-patient addressable market. Castle intends to maintain test availability while balancing shareholder interests and gross margin pressure. The company plans to pursue reconsideration requests and alternative Medicare contractor pathways but acknowledges uncertainty in regaining coverage.
2. Re-focusing Sales Efforts on DecisionDx-Melanoma
In response to the Medicare coverage headwind, Castle will shift its dermatology salesforce focus nearly 100% toward DecisionDx-Melanoma starting May 2025. This reallocation aims to accelerate penetration in a 130,000-patient addressable market with only 28% current penetration. Management anticipates mid to high single-digit volume growth in melanoma tests for 2025, though Q1 is expected to reflect typical seasonality and a flat to slightly down volume versus Q4 2024.
3. TissueCypher Expansion in Gastroenterology
TissueCypher’s test report volume surged 130% in 2024, driven by commercial team expansion and growing clinical guideline recognition, including endorsement by the American Gastroenterological Association. The company targets a 415,000-patient addressable market with approximately 5% penetration exiting 2024. Continued salesforce growth and clinician education are expected to sustain significant volume growth, albeit at a moderated pace versus 2024’s exceptional increase.
4. Pipeline Development and Resource Allocation
Castle is advancing its atopic dermatitis gene expression profile test, targeting a late 2025 launch contingent on successful validation. Reimbursement strategy discussions will follow launch, with material revenue expected not before 2028 or 2029. The company remains disciplined on capital allocation, balancing internal R&D, commercial investments, and selective external strategic opportunities aligned with existing verticals.
5. Financial Discipline and Cash Flow Generation
Castle’s $293.1 million cash position and positive operating cash flow provide a solid foundation for growth initiatives and potential acquisitions. Despite increased personnel and marketing expenses, the company’s profitability and cash flow trajectory support continued investment while maintaining financial flexibility.
Key Considerations
Castle’s 2024 results underscore strong commercial execution and product adoption across multiple franchises, but the Medicare non-coverage of DecisionDx-SCC introduces a significant near-term challenge.
- Medicare Coverage Risk: The loss of Medicare reimbursement for DecisionDx-SCC could materially reduce test volumes and revenue in 2025, requiring strategic commercial adjustments.
- Salesforce Reconfiguration: The shift to a near-exclusive focus on melanoma tests may accelerate penetration but risks short-term volume disruption during transition.
- Pipeline Timing: Atopic dermatitis test launch and reimbursement remain several years away, limiting near-term contribution but representing a longer-term growth vector.
- Margin Pressure: Anticipated gross margin compression to low to mid 70% range in 2025 due to SCC reimbursement loss and inflationary cost pressures.
- Cash Flow Seasonality: First quarter historically experiences net operating cash use due to bonuses and benefits, important for modeling 2025 cash flow.
Risks
Castle faces regulatory and reimbursement risks, particularly the impact of Novitas’ LCD non-coverage decision on DecisionDx-SCC, which could constrain revenue and margins. Competitive pressures, slower-than-expected clinical adoption, and uncertainties in pipeline product validation and reimbursement also pose execution risks. Macroeconomic factors such as inflation and supply chain disruptions may increase operating costs.
Forward Outlook
For Q1 2025, Castle expects:
- Flat to slightly down DecisionDx-Melanoma volume reflecting seasonality and holiday impacts.
- Continued momentum in TissueCypher volume, though at a moderated growth rate versus 2024.
For full year 2025, management guides total revenue of $280 to $295 million, factoring in the anticipated Medicare non-coverage of DecisionDx-SCC from late April. The company expects adjusted gross margins in the mid to high 70% range and remains committed to positive adjusted EBITDA and net operating cash flow for the year. Management highlighted ongoing efforts to regain SCC reimbursement and strategic capital allocation to support growth and shareholder value.
Takeaways
Castle Biosciences enters 2025 with strong momentum but faces a pivotal reimbursement challenge that will test its commercial agility and strategic focus.
- Volume and Revenue Growth: Robust 2024 growth across dermatology and gastroenterology confirms market acceptance and execution strength, underpinning long-term potential.
- Medicare Headwind and Strategic Response: Loss of DecisionDx-SCC Medicare coverage necessitates near-total salesforce reallocation to melanoma, with uncertain timing and magnitude of reimbursement recovery.
- Pipeline and Capital Allocation: The atopic dermatitis test represents a promising but distant growth opportunity, while strong cash flow and balance sheet enable opportunistic investments aligned with core verticals.
Conclusion
Castle Biosciences demonstrated exceptional revenue and volume growth in 2024, driven by diversified test portfolios and expanding clinical adoption. However, the Medicare reimbursement setback for DecisionDx-SCC introduces a key risk that management is addressing through salesforce realignment and reimbursement advocacy. The company’s strong financial position and pipeline investments position it well for sustained growth, contingent on navigating reimbursement and competitive dynamics in 2025 and beyond.
Industry Read-Through
Castle’s experience highlights the critical influence of Medicare coverage decisions on diagnostics companies’ revenue trajectories and commercial strategies. The shift in salesforce focus following reimbursement changes underscores the importance of portfolio diversification within specialty diagnostics. TissueCypher’s rapid adoption exemplifies growing acceptance of spatial omics and personalized risk stratification in gastroenterology, signaling a broader industry trend toward precision diagnostics. Other diagnostics firms should watch reimbursement developments closely and maintain operational flexibility to reallocate commercial resources swiftly in response to coverage changes.